53 results about "Apolipoprotein A1" patented technology

Oligonucleotide compounds modulate expression and/or function of an apolipoprotein (ApoA1) polynucleotides and encoded products thereof. Methods for treating diseases associated with apolipoprotein-A1 (ApoA1) comprise administering one or more Oligonucleotide compounds designed to inhibit the Apo-A1 natural antisense transcript to patients.

The present invention provides peptidomimetics derived from Apolipoprotein A-I, which is useful for beneficially influencing lipid parameters and/or plasma cholesterol levels. The invention also provides pharmaceutical compositions and methods of treatment for elevated levels of plasma cholesterol.

Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL-1-beta, Brain-Derived Nerotrophic Factor, Apolipoprotein A1, Serum Amyloid P, Growth Hormone, Beta-2 microglobulin, Lipoprotein (a), MMP-9, Thyroid Stimulating hormone, alpha-2 Macroglobulin, Complement 3, IL-7, Leptin, and IL-6. Kits containing reagents to assist in the analysis of fluid samples are also described.

The invention relates to a method of diagnosing non-alcoholic steatohepatitis (NASH) using molecular markers. The inventive method consists in detecting and quantifying, in vitro in a hepatic tissue sample, the levels of a protein which can be used as a NASH molecular marker and which is selected from apolipoprotein A1, sub-unit β of the mitochondrial ATPase, leukotriene A4 hydrolase, keratin 18, guanidine acetate N-methyltransferase, superoxide dismutase, albumin, antioxidant protein 2 (isoform 1), prohibitin 1, methionine adenosyl transferase, long-chain acyl CoA dehydrogenase, selenium binding protein, antioxidant protein 2 (isoform 2), and combinations of same. The invention further consists in comparing the results obtained with the normal values of said proteins in healthy hepatic tissue. Said method can be used to diagnose NASH and/or to assess a patient's potential risk of developing NASH.

Biomarkers, biomarker panels and methods for diagnosing osteoarthritis (OA) are disclosed, using measurement of the expression level of certain polypeptides in a test sample from a subject, including MCP1, IL8, KC, MMP2, MMP3, IL6, MMP1, RANTES, MMP9, IL1B, Apolipoprotein A1, Apolipoprotein E, DCN, CILP and COMP. Related methods for monitoring OA treatment efficacy, diagnostic reagents, and kits are also described.

Described are new methods for promoting the expression of apolipoprotein A1 (APO A1) for increasing levels of HDL, and assays for screening and identifying compounds for regulating expression of the APO A1 protein.

The invention discloses a VHH chain of a single-domain antibody for apolipoprotein A1. The VHH chain comprises a frame region FR and a complementary determining region CDR. The invention discloses amino acid sequences of the frame region FR selected from the following group of FR and the amino acid sequences of the complementary determining region CDR. The invention also discloses two types of single-domain antibodies for the apolipoprotein A1, also discloses two types of DNA molecules for coding the VHH chain of the single-domain antibody for the apolipoprotein A1 mentioned in the invention or the single-domain antibody for the apolipoprotein A1 mentioned in the invention, also discloses a host cell for expressing the single-domain antibody for the apolipoprotein A1, and also discloses the application of the single-domain antibody for the apolipoprotein A in detection of the apolipoprotein A1. Through the gene sequences and the host cell of the single-domain antibody disclosed by the invention, the single-domain antibody can be efficiently expressed in colon bacillus and applied in research and development of an apolipoprotein A1 detection reagent.

The invention discloses a preparation method for a calibration matter for calibrating apolipoprotein A1 and apolipoprotein B. The essentials of the technical scheme are as follows: the preparation method comprises the following steps: (1) adding a multi-anionic compound and divalent metal ions into blood serum to carry out pre-treatment; (2) extracting low density lipoprotein (LDL); (3) extracting high density lipoprotein (HDL); (4) mixing protein and base blood serum to prepare the calibration matter; (5) defining the value of the calibration matter. The preparation method has the advantages that the extraction of LDL and HDL components in the blood serum by a multi-anionic compound and divalent metal ion sub-step precipitation method is simplified; the content of the ApoB and the content of the ApoA1 are detected; the calibration matter can be mixed into the blood serum of healthy people according to the needed amount so that the ApoA1 and the ApoB reach the predicated content; the method is simple; a stabilizer and a turbidity-preventing agent are added into the mixed blood serum so that the prepared freeze-dried calibration matter is clarified after being re-dissolved; the stability is good and a base material effect does not exist; the calibration matter is diluted into five different concentrations and can be used for non-linear calibration of determining the ApoA1 and the ApoB on an automatic analyzer.

The present invention provides, in part, methods for identifying inhibitors of NRIP1 and methods of using such inhibitors. Methods of treating NRIP1-mediated disorders using NRIP1 inhibitor are also provided.

A molecular diagnosis system of ovarian cancers encompasses a detection device configured to obtain a detected value of an expression amount of an apolipoprotein A1 gene in ovarian tissue as a diagnosis subject, a storage device configured to store a normal value of the expression amount of the apolipoprotein A1 gene in normal ovarian tissue, and a determination mechanism configured to determine that the ovarian tissue as the diagnosis subject is clear cell adenocarcinoma when the detected value is lower than the normal value.

The invention discloses an entecavir high-density lipoprotein enveloping preparation, and a preparation method and a use thereof. The entecavir high-density lipoprotein enveloping preparation contains entecavir, phospholipid, cholesterol and ApoAl in the weight ratio of 5: 7: 3: (5-20).

The invention provides an apolipoprotein A1 purification method. The method is as below: obtaining a plasma sample, and clarifying the sample; conducting a first hydrophobic chromatography on the plasma sample after clarification, so as to obtain a first purification product; degreasing the first purification product; and conducting a second hydrophobic chromatography on the first purification product after degreasing treatment. The first purification elution includes twice elution, the first elution uses 5-10% organic alcohol, and the second elution uses 25-30% alcohol; and the second hydrophobic chromatography uses alcohol eluate with elution strength lower than 25-30%. The method of the invention uses strong hydrophobic mechanism of the lipid in an HDL structure for the first purification, and then the lipoprotein structure with destroyed HDL makes the apolipoprotein A1 separate from the lipid, so that hydrophobicity difference between the apolipoprotein A1 and complex protein with the same high hydrophobicity increases, hydrophobic separation occurs again, and apolipoprotein A1 with high purity can be obtained. The method is simple and novel, and has large sample treatment amount and high efficiency.

The invention discloses a composite calibration product containing six indexes and having high anti-interference ability, and a preparation method thereof, and relates to the field of biotechnology. The matrix of the composite calibration product is serum, the six index components are apolipoprotein A1, apolipoprotein B, high density lipoprotein cholesterol, low density lipoprotein cholesterin, total cholesterol and triglyceride, and the matrix contains anti-interference substances: mannitol, Genapol X 80, ascorbic acid, Emulgen A90, FAD, ADP, polyoxyethylene 8000 and glutathione. According tothe composite calibration product disclosed by the invention, the anti-interference substances are fully and evenly mixed at first, and then the 6 indexes are added in sequence, so that full play isgiven to the anti-interference substances added to the serum matrix, and the prepared composite calibration product can not only reduce the interference between a plurality of indexes in the product,but also can improve the stability.

The invention provides an apolipoprotein A1 detection kit. The apolipoprotein A1 detection kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises 0.8 to 51g/L of octylphenoxypolyethoxyethanol; the reagent R2 comprises 0.8 to 51g/L of octylphenoxypolyethoxyethanol, 0.01 to 15.5g/L magnesium salt, 0.01 to 20g/L of lime acetate, and an antibody. The kit is good in antibody performance and repeatability, and accurate in reagent detection result, and can meet the use requirement.

The invention provides a blood-lipoid and special protein composite quality control product. The blood-lipoid and special protein composite quality control product is prepared from twelve components of C3, C4, apolipoprotein A1, apolipoprotein B, high-density lipoprotein, low-density lipoprotein, C-reactive protein, IGA, IGM, IGG, total cholesterol and glycerinum, and addition is carried out according to the order. A used matrix is calf serum, and inductive anti-interference matter is 2.0-10% of BSA, 5ml/L of polyethylene glycol, 1-20g/L of PEG20000, 2g/L of sodium fluoride and 0.5-1.5% of ATP. Composite quality control freeze dried aquatic products are prepared with the help of a freeze-drying technology.

Provided are methods for diagnosing ovarian cancer or assessing the risk of developing ovarian cancer in a subject by measuring, in a biological sample from the subject, the amount of IL-6 and comparing the amount of IL-6 measured to a predetermined IL-6 cutoff value. Also provided are methods that further include measuring, in the biological sample, the amount of two or more biomarkers selected from the group consisting of transthyretin, apolipoprotein A1, transferrin, β-2 microglobulin, and CA 125 II. The amount of IL-6 and biomarkers are useful in the diagnosis of ovarian cancer, and individuals can be identified as having ovarian cancer when the amount of IL-6 is greater than the IL-6 cutoff value and/or the biomarker score is greater than the biomarker score cutoff value.

The invention provides a multi-protein combined biomarker, application and a heart valvular disease complicated with atrial fibrillation diagnostic kit. The multi-protein combined biomarker is composed of an apolipoprotein A1 protein antibody, an angiotensin antigen antibody, an LIM structural domain protein 7, a macrophage colony stimulating factor receptor 1, a vitronectin antibody and a prothrombin fragment F1 + 2 antibody. Modern biological technology and bioinformatics analysis find that combined application of the six proteins has the application of predicting valvular heart disease complicated with atrial fibrillation, can be applied to preparation of targeted drugs for early intervention of related diseases, and can also be applied to preparation of a heart valvular disease complicated with atrial fibrillation screening kit. According to the kit, modeling is carried out after the concentrations of the six proteins are measured, and good evaluation efficiency and potential hugeapplication value are achieved on whether atrial fibrillation happens to a patient suffering from the heart valvular disease or not.